EMA Authorised: Hetlioz (tasimelteon) — Vanda Pharmaceuticals Netherlands B.V.

View source ↗

Summary

Hetlioz (tasimelteon) has been authorised in the EU for a circadian rhythm sleep-wake disorder, notably non-24-hour sleep-wake rhythm disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Circadian Rhythm Sleep-wake Disorder
• Non-24-hour Sleep-wake Rhythm Disorder

Drugs mentioned

• Hetlioz (tasimelteon)

Snippet

Status: Authorised. Therapeutic area: Sleep Disorders, Circadian Rhythm. MAH: Vanda Pharmaceuticals Netherlands B.V.. Decision date: 10/10/2022